Please assess the completion status of the following clinical trial:

Trial Title: Topical Menthol for the Treatment of Chemotherapy Induced Peripheral Neuropathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age≥21 years~2. History of stage I-III breast, gastrointestinal or gynecologic cancer~3. Must have received at least one taxane or platinum based chemotherapy drug within two years prior to enrollment.~4. Must exhibit a typical symptom of CIPN that was not present prior to chemotherapy. Symptoms include numbness, tingling, thermal hyperalgesia, cold allodynia in the hands and/or feet, muscle weakness or unsteady gait in at least two of the last seven days prior to registration.~5. Signed informed consent~6. Concomitant biologic, hormonal, or radiation therapy are acceptable~7. Narcotics, antidepressants or other medications for the treatment of CIPN are permitted, if patient on a stable dose for at least one month prior to enrollment~Exclusion Criteria:~1. Previous treatment with topical menthol (menthol/methylsalicylate products like BenGay, Aspercreme, or Icy Hot) of any concentration within the previous 3 months~2. Known diabetic neuropathy~3. Severe concomitant illnesses~4. Known allergy or preexisting skin disease which prohibits use of menthol~5. Any topical treatment for neuropathy or other serious skin condition on the hands or feet.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- topical menthol (Type: EXPERIMENTAL): Patients with neuropathic pain will receive topical menthol following or during chemotherapy for the treatment of either breast, gastrointestinal, or gynecologic cancer.
- placebo lotion (Type: ACTIVE_COMPARATOR): Patients with neuropathic pain will receive placebo lotion following or during chemotherapy for the treatment of either breast, gastrointestinal, or gynecologic cancer.

Based on this trial design, predict the completion outcome and termination type (if applicable).